PMV Pharmaceuticals, Inc. (PMVP) PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
PMV Pharmaceuticals, Inc. NASDAQ:PMVP Healthcare · Biotechnology
Mkt Cap $98.92M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors, adding more than two decades of healthcare investing experience.
The appointment follows completion of enrollment in the Phase 2 monotherapy portion of the pivotal PYNNACLE trial of rezatapopt, with an NDA submission for accelerated approval in TP53 Y220C platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Rezatapopt holds FDA Fast Track and Orphan Drug designations; the board addition is a governance update ahead of the commercialization push rather than a program change.
• 27d ago AI analysis › Press Release ⚠ 1
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals appointed Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, its first-in-class p53 reactivator.
The company reiterated plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, with enrollment in the Phase 2 PYNNACLE trial being completed.
Herman brings more than 24 years of oncology and rare disease commercial experience, including CCO roles at Repare Therapeutics and Y-mAbs Therapeutics, where he led the DANYELZA launch.
• 1mo ago AI analysis › Press Release
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PMV Pharma priced an oversubscribed $50.8 million public offering consisting of common stock, pre-funded warrants, and accompanying warrants.
The offering includes units priced at $1.21 for one share of common stock plus one warrant, or $1.20999 for one pre-funded warrant plus one warrant, with warrants exercisable at $1.21.
TD Cowen is acting as the sole book-running manager, and the offering is expected to close on or about September 2, 2026.
• 2mo ago AI analysis › Press Release
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharma announced a proposed public offering of common stock, accompanying warrants, and pre-funded warrants to purchase common stock.
TD Cowen is acting as the sole book-running manager for the offering, which will be conducted pursuant to a shelf registration statement on Form S-3.
The company stated that there can be no assurance regarding the completion, timing, size, or terms of the offering.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharma reported updated interim data from the Phase 2 PYNNACLE trial showing a 46% objective response rate and a 10.0-month median duration of response for rezatapopt in platinum-resistant ovarian cancer.
The FDA provided feedback supporting an NDA submission strategy for accelerated approval based on the Phase 2 data, with the company planning to file in the first quarter of 2027.
Rezatapopt demonstrated a favorable safety profile with a 5% discontinuation rate due to treatment-related adverse events, with full primary analysis data expected in the fourth quarter of 2026.
• 2mo ago AI analysis › Press Release ● Major ⚠ 1
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals completed enrollment for the Phase 2 monotherapy portion of the PYNNACLE trial evaluating rezatapopt in platinum-resistant ovarian cancer, with an NDA submission now planned for the first quarter of 2027.
Financially, the company reported $79.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing an expected cash runway into the second quarter of 2027.
The net loss for the second quarter narrowed to $18.1 million from $21.2 million a year ago, driven by lower R&D expenses of $14.7 million compared to $18.4 million in the prior year.
• 2mo ago AI analysis › Press Release
PMV Pharmaceuticals Announces Board Chair Transition
Laurie Stelzer has been appointed Chair of the Board of PMV Pharmaceuticals, effective at the company's 2026 Annual Meeting on June 4, 2026, succeeding Rich Heyman, Ph.D.
Dr. Heyman will not stand for reelection, concluding his tenure, while Ms. Stelzer brings over 25 years of financial and biopharmaceutical leadership experience to the role.
The transition coincides with continued enrollment in the registrational PYNNACLE trial for rezatapopt, with the company anticipating a New Drug Application submission in the first quarter of 2027.
• 6mo ago AI analysis › 
